Stephens Consulting’s Syndax Pharmaceuticals SNDX Stock Holding History

Stephens Consulting’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30	Closed	-$369	–	1886
2025 Q1	$369	Buy	+30	New	+$423	﹤0.01%	1209

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Stephens Consulting's SNDX Position: Q2 2025 in Review

Stephens Consulting sold out of Syndax Pharmaceuticals (SNDX) in Q2 2025, closing a stake of 30 shares — an estimated $369 sold.

Stephens Consulting first reported a position in SNDX in Q1 2025 and held it in 1 quarter. The position peaked at $369 in Q1 2025. 216 funds tracked by Wall St. Rank hold SNDX as of Q2 2025.

Stephens Consulting reported no remaining Syndax Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 30 Syndax Pharmaceuticals shares in Q2 2025, an estimated $369.
Stephens Consulting first reported a position in Syndax Pharmaceuticals in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Syndax Pharmaceuticals position peaked at $369 in Q1 2025.
216 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.